High risk injection drug use and uptake of HIV prevention and treatment services among people who inject drugs in KwaZulu-Natal, South Africa

Authors: Brian C. Zanoni^{a,b,c}, Cecilia Milford^d, Kedibone Sithole^d, Nzwakie Mosery^d, Michael Wilson ^{e, f}, Shannon Bosman ^g, Jennifer Smit^d

^a Emory University, Atlanta, Georgia, United States of America

^b Children's Healthcare of Atlanta, Atlanta, Georgia, United States of America

° Rollins School of Public Health, Atlanta, Georgia, United States of America

^d Wits MRU (MatCH Research Unit), Department of Obstetrics and Gynaecology, Faculty of

Health Sciences, University of the Witwatersrand, Durban, South Africa

^e Advance Access & Delivery, Durban, South Africa

^f Department of Health Behaviour, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA

^g Centre for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa

§ Corresponding Author:

Brian C. Zanoni, MD, MPH 2015 Upper Gate Drive NE Atlanta, GA 30322 bzanoni@emory.edu +1 (404) 727 - 0284

Word Count:

Abstract: 130 Article: 1742

Abstract:

The use of injection drugs in South Africa is increasing. HIV prevention, treatment and addiction services for people who inject drugs (PWID) in South Africa are not well documented. We conducted a mixed-methods study to understand current drug use practices and access to HIV prevention and treatment services for PWID in KwaZulu-Natal, South Africa. We used respondent-driven sampling to recruit 45 people who reported injecting opiates within the past 6 months from Durban, KwaZulu-Natal, South Africa. We found high rates of practices that increase HIV/viral hepatitis risk including the use of shared needles (43%) and direct blood injections (bluetoothing) (18%). Despite 35% of participants living with HIV, only 40% accessed antiretroviral therapy within the past year, and one accessed PrEP. None of the participants reported ever testing for Hepatitis C.

1 Introduction:

2 South Africa has an estimated 7.9 million (95% CI: 7.1 million – 8.8 million) individuals living 3 with HIV, and KwaZulu-Natal has the highest HIV prevalence in the country. (1) In South Africa, 4 there are approximately 5 million people accessing antiretroviral therapy (ART), making it the 5 largest national antiretroviral program in the world. (1) However, hidden populations remain that 6 are not reached in the HIV prevention and care continuum, and efforts to expand HIV 7 prevention, HIV testing and linkage to care services in sub-Saharan Africa have largely targeted 8 non-injection drug using communities. (2, 3) Before a recent increase in people who inject drugs 9 (PWID) in South Africa, it was estimated that 21% of PWID in South Africa were living with HIV 10 (2, 4) compared to 14% in the general population. (1) In the general population 74% of people 11 living with HIV are accessing ART while only 40.5% of PWID and living with HIV are accessing 12 ART.(2) A recent increase in injection drug use, coupled with poor access to addiction services 13 in the forms of needle exchanges or medication assisted therapy (such as methadone or 14 buprenorphine), has led to the increase in a sequestered population that has potential to 15 reverse many of the investments and gains in public health access to HIV prevention and 16 treatment services. (5) The population of PWID in South Africa spans groups of homeless, sex 17 workers, and working-class individuals, bridging multiple social networks contributing to the 18 potential increase in HIV incidence among individuals not targeted in typical HIV continuum 19 interventions. (6)

20

Whoonga, an opiate-based drug of abuse, has been present in KwaZulu-Natal for more than 10 years, yet has only recently seen an increase in injection use. (7, 8) In the past, Whoonga was typically smoked; however, intravenous and subcutaneous administration has become more prevalent. (9) The recent increase in cases of infective endocarditis in South Africa is indicative of an increase in injection drug use. (5, 7, 8) In addition, the dangerous practice of "bluetoothing" in which blood is withdrawn from one individual who has recently injected a drug

27 and directly injected intravenously into another person, has been reported. (10, 11) Called flash-28 blooding in other African countries, this practice is often performed in settings of poverty and 29 poor access to needles or needle exchange programs. (12-14) This practice, in addition to 30 needle sharing, has potential to increase the risk of HIV and viral hepatitis among PWID and 31 spill over into the general population through sexual networks. (15-18) 32 33 Given the limited data on the population of individuals using injection drugs in KwaZulu-Natal, 34 South Africa, we conducted a mixed-methods, respondent-driven study to understand drug use 35 practices and current access to health care in preparation for targeted prevention and treatment 36 interventions. 37 38 Methods:

We used respondent driven sampling (RDS) to recruit individuals aged 18 years or older, with self-described use of injection drugs within the last 6 months, and currently living in KwaZulu-Natal, South Africa. We excluded individuals who did not speak either English or isiZulu, who were severely or visibly intoxicated, or those with severe mental or physical illness preventing participation in informed consent procedures.

44

We recruited three initial seed individuals (who also reported injection drug use in the past 6 months) who were attending a harm reduction center in Durban, South Africa. These three seed individuals were encouraged to recruit up to three other PWID from their individual social network. Each additional participant was also asked to recruit up to three different individuals from their own social network, until we reached a total sample of 45 participants. After providing written informed consent, participants completed a facilitated questionnaire that collected information on sociodemographics, drug use, sexual behavior and network characteristics, HIV

- 52 testing practices, and use of HIV prevention or treatment services. Interviewers entered data
- 53 directly into a REDCap database as questions were answered. (19)
- 54
- 55 We assessed the frequency, type, and methods of drug use, information on needle
- 56 procurement, use, and sharing using the National HIV Behavior Surveillance System; (20) and
- 57 WHO ASSIST. (21) HIV risk assessment including sex work, number of sexual partners,
- condom use and frequency of condom use within the past 3 months was assessed by the Texas
- 59 Christian University HIV/Hepatitis Risk Assessment. (22) We also evaluated access to health
- 60 care by exploring knowledge of HIV status, HIV testing in the past 12 months, access and use
- of medical services in the past 12 months, knowledge and acceptability of HIV self-testing.
- 62
- 63 For this descriptive analysis we used standard summary statistics (e.g. counts/percentages;
- 64 median and interquartile range of continuous measures). Basic descriptive data analyses were
- 65 performed using REDCap. Results of additional in-depth interviews are reported separately.
- 66
- This study was approved by the Institutional review Boards of Emory University, the University
 of Witwatersrand and the KwaZulu-Natal National Department of Health.
- 69

70 Results:

- 71 We interviewed 45 individuals in Durban, South Africa who reported recent injection drug use
- using respondent-driven sampling from November 1, 2021 to February 8, 2022. Participants had
- a median age of 28.5 years (IQR 26.6 32.3) and were predominantly male (58%; n=26),
- heterosexual (91%; n=41), had completed secondary education (87%; n=39), and were
- currently (76%; n=32) or recently (92%; n=42) homeless as indicated by **Table 1**.
- 76

77	The median reported starting age of injecting drug use was 22 years (IQR 19 – 26). The
78	majority of participants did not use alcohol (64%; n=29) but reported use of other drugs (53%;
79	n=24). Most participants (93%; n=42) reported use of injection drugs within the last month, with
80	91% (n=41) reporting averaging more than one injection per day. All participants (100%)
81	reported daily use of Whoonga. Opioid overdoses were personally experienced in 22% (n=10)
82	of participants in the last year, with a median of 3.5 (IQR $2 - 4.75$) individual episodes of
83	overdosing. Sixty four percent (n=28) knew others who had experienced a lethal overdose in the
84	last year.
85	
86	All participants (100%) reported ever re-using needles or equipment with 42% (n=19) reporting
87	use of shared needles in the past year and 73% (n=33) reported sharing other drug preparation
88	or use materials. The majority accessed (64%; n=29) and disposed (56%; n=25) of their needles
89	through needle exchange programs. Bluetoothing was practiced in 18% (n=8) of individuals in

90 the last 12 months.

91

More than half (60%; n=27) had ever participated in a drug treatment program. The majority
(96%; n=43) had ever tested for HIV. Thirty-five percent of individuals (n=15) were known to be
living with HIV but only six (40%) reported accessing antiretroviral therapy within the past 12
months. Only one individual (2%) was taking pre-exposure prophylaxis (PrEP). None of the
participants had ever tested for Hepatitis C.

97

98 Discussion:

In this study we found high rates of unsafe injection drug practices that included sharing and reusing needles and drug preparation materials, as well as the practice of directly injecting blood from an individual who had recently injected (bluetoothing). These practices, if widespread amongst PWID, coupled with the low uptake of treatment and preventative services described in

this study, including HIV testing, PrEP and ART services, could negate some of the efforts
made in the HIV prevention and treatment continuum of care in South Africa.

105

The current and substantial efforts to combat the HIV epidemic in South Africa do not adequately address the needs of PWID. Although efforts are increasing to routinely screen for alcohol use in HIV care across South Africa, (23) screening for drug use (and injection drug use specifically) is not routinely conducted, and treatment for drug use disorder is rarely integrated with HIV care services.

111

112 While the COVID-19 pandemic slowed progress globally to provide access to harm reduction 113 and health services to people who use drugs, parts of South Africa saw a positive shift from a 114 once, a prohibitionist stance to dealing with drug use disorder to one that supports the provision 115 of evidence-based harm reduction practices, especially to low-income and homeless people 116 who use drugs. Nationally, needle exchange programs, harm reduction services, and 117 medication assisted treatment are often difficult to access either due to their high-priced, fee-for-118 service models or limited availability. (24) KwaZulu-Natal's only needle and syringe exchange 119 program in Durban was reinstated during the COVID-19 lockdown, and the country's first low-120 threshold harm reduction center was started in Durban to provide daily opiate substitution 121 therapy to more than 200 PWID. The limited resources available for harm reduction services 122 have historically resulted in punishment of substance use as the predominant response by law 123 enforcement to opiate addiction. (25) However after the COVID-19 lockdowns, Durban also saw 124 a dramatic shift in the way that law enforcement engaged with people who use drugs, shifting 125 the narrative of police as punitive to one of protectors and advocates of health services for 126 PWID. (26, 27) Continued work is needed to reduce ongoing stigma towards PWID which limits 127 access to HIV prevention services and harm reduction programs. (28, 29)

128

Without the availability of widespread interventions, injection drug use has continued to increase in South Africa with a prevalence of 0.6% in a population based survey in 2012 with 0.2% reporting Whoonga use. (30) However, small pilot studies have shown high retention rates, opiate reduction, and improvement in mental health in individuals accessing methadone treatment in South Africa. (31) Nevertheless, the lack of routine hepatitis C testing and access to PrEP indicate significant gaps in service delivery. Integration of harm reduction services into routine healthcare could impact the rising use of opiates and the HIV epidemic in South Africa.

137 The major limitations of this study include the small sample size and descriptive nature of this 138 preliminary study. In addition, this study was conducted during the COVID-19 pandemic when 139 services were interrupted by various lockdown policies. During this time, there was also an 140 influx of new people into the city who may not have been familiar with available services. Unsafe 141 drug use practices may have occurred as a result of disruption of needles and other safe use 142 supplies during lockdown. However, we are encouraged by the ability to recruit a difficult to 143 reach population through respondent-driven sampling over a short period of time (3 months) 144 and using only 3 initial seed individuals.

145

146 <u>Conclusion:</u> The increased prevalence of injection drug use in South Africa along with unsafe 147 injection practices and low uptake of preventative and treatment services, in particular HIV 148 related services, has potential to reverse the significant gains made in HIV prevention services. 149 Integration of addition services, medication assisted treatment and access to HIV prevention 150 and treatment services could improve the lives of PWID and reduce the burden of HIV in this 151 population.

152 **Table 1:** Descriptive statistics of individuals recruited through respondent-driven sampling and

self-reporting recent injection drug use in KwaZulu-Natal, South Africa.

154

Characteristic	Participants n (%) N=45		
Demographics			
Median Age (years)(IQR)	28.5 (26.6 – 32.3)		
Male	26 (58%)		
Heterosexual	41 (91%)		
Single	17 (39%)		
Long term partner but not married and not living together	26 (59%)		
Several casual partners	2 (5%)		
South African citizen	45 (100%)		
Education			
Primary education	4 (9%)		
Secondary education	39 (87%)		
Tertiary level	2 (4%)		
Median grade completed (IQR)	10 (10 – 11)		
Employment			
Full time employed	1 (2%)		
Employed part time	11 (24%)		
Unemployed	17 (38%)		
Housing			
Homeless in the past 12 months	42 (93%)		
Currently homeless	32 (76%)		
Alcohol Use			
No alcohol in the past year	29 (64%)		
Binge drinking more than once a month	10 (22%)		
Injection drug use			
Used injection drugs	45 (100%)		
Median age at first use (years) (IQR)	22 (19 – 26)		
Last used injection drugs in the past month	42 (93%)		
Injecting more than once a day	41 (91%)		
Injecting daily	2 (4%)		
Injecting more than once a week	2 (4%)		
Using Whoonga/heroin daily or more	45 (100%)		
Had an opioid overdose (in last year)	10 (22%)		
Median number of opioid overdoses (IQR) (in last year)	3.5 (2 – 4.75)		
Know of others who experienced lethal opioid overdose (in last year)	29 (64%)		
Median overdose deaths known about (in last year)	2 (1 -3)		
Know of others with non-lethal opioid overdose (in last year)	28 (62%)		
Most common place acquired needles			
Needle exchange or NGO	29 (64%)		

Friend / acquaintance	4 (11%)		
Pharmacy	1 (4%)		
Dispose of needle			
Needle exchange or NGO	25 (56%)		
On the street	8 (8%)		
Trash	7 (16%)		
High risk Injection Drug Use			
New / unused Needle use in last 12 months			
Always	14 (31%)		
Sometimes	22 (49%)		
Rarely	9 (20%)		
Never	0 (0%)		
Median number of people shared needles with in last 12 months (IQR)	0 (0 -3)		
Median number of people shared other drug-	3 (0 – 5)		
use material with in last 12 months (IQR)			
Median number of people shared drugs with	3 (1 – 4)		
in the last 12 months (IQR)			
Used a shared needle in the past 12 months	19 (42%)		
Used shared material in last 12 months	33 (73%)		
Bluetoothing in the last 12 months	8 (18%)		
Re-used needle from someone else at last injection	10 (22%)		
Bluetoothing at last injection	2 (4%)		
Did not dispose of needle at last injection	29 (64%)		
Injected with known HIV+ individual	6 (13%)		
Other drug use in last year	24 (53%)		
Healthcare Services			
Participated in a drug treatment program	27 (60%)		
Ever tested for HIV	43 (96%)		
Known to be living with HIV	15 (35%)		
Accessing ART in the last 12 months	6 (40%)		
Median number of HIV tests in last 2 years	3 (1 – 8.5)		
Never tested for Hepatitis C	45 (100%)		
Currently taking PrEP	1 (2%)		
Interested in PrEP	24 (53%)		

Competing Interests:

The authors have no conflicts of interest relevant to this article to disclose.

Author's Contributions:

Dr. Zanoni conceptualized and designed the study, performed the data analysis, drafted the initial manuscript, reviewed and revised the manuscript and approved the final manuscript as submitted.

Kedibone Sithole performed the data collection, contributed to the drafting of the manuscript, critically reviewed the manuscript and approved the final manuscript as submitted.

Nzwakie Mosery performed the data collection, contributed to the drafting of the manuscript, critically reviewed the manuscript and approved the final manuscript as submitted.

Michael Wilson assisted with the conceptualization and design of the study, contributed to the data collection, and critically reviewed the manuscript, and approved the final manuscript as submitted.

Shannon Bosman contributed to the data collection, and critically reviewed the manuscript, and approved the final manuscript as submitted.

Cecilia Milford assisted with the conceptualization and design of the study, contributed to the analysis plan, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Jennifer Smit assisted with the conceptualization and design of the study, contributed to the analysis plan, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Funding:

This work was supported via: Center for AIDS Research at Emory University (P30AI050409)

References:

1. Zuma K, Simbayi L, Zungu N, Moyo S, Marinda E, Jooste S, et al. The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey. Int J Environ Res Public Health. 2022;19(13).

2. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2021. Joint United Nations Programme on HIV/AIDS; 2021.

3. Zanoni BC, Elliott RJ, Neilan AM, Haberer JE. Screening for HIV and linkage to care in adolescents: insights from a systematic review of recent interventions in high- versus low- and middle-income settings. Adolesc Health Med Ther. 2018;9:211-35.

4. Scheibe A, Young K, Moses L, Basson RL, Versfeld A, Spearman CW, et al. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey. Harm Reduct J. 2019;16(1):28.

5. Meel R, Essop MR. Striking increase in the incidence of infective endocarditis associated with recreational drug abuse in urban South Africa. S Afr Med J. 2018;108(7):585-9.

6. Parry CD, Carney T, Petersen P, Dewing S, Needle R. HIV-risk behavior among injecting or non-injecting drug users in Cape Town, Pretoria, and Durban, South Africa. Subst Use Misuse. 2009;44(6):886-904.

7. Grelotti DJ, Closson EF, Smit JA, Mabude Z, Matthews LT, Safren SA, et al. Whoonga: potential recreational use of HIV antiretroviral medication in South Africa. AIDS Behav. 2014;18(3):511-8.

8. Rough K, Dietrich J, Essien T, Grelotti DJ, Bansberg DR, Gray G, et al. Whoonga and the abuse and diversion of antiretrovirals in Soweto, South Africa. AIDS Behav. 2014;18(7):1378-80.

9. Tyree GA, Mosery N, Closson EF, Mabude Z, du Toit C, Bangsberg DR, et al. Trajectories of initiation for the heroin-based drug whoonga - qualitative evidence from South Africa. Int J Drug Policy. 2020;82:102799.

10. Face-to-Face Africa. Report reveals shocking "bluetoothing" habit among drug addicts in South Africa 2019 [Available from: <u>https://face2faceafrica.com/article/report-reveals-shocking-bluetoothing-habit-among-drug-addicts-in-south-africa-video</u>.

11. Aparks J. "Bluetoothing": Why addicts in South Africa are injecting each other's blood: Sky News; 2019 [Available from: <u>https://news.sky.com/story/bluetoothing-why-addicts-in-</u><u>south-africa-are-injecting-each-others-blood-11388290</u>.

12. Asher AK, Hahn JA, Couture MC, Maher K, Page K. people who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa. J Assoc Nurses AIDS Care. 2013;24(6):e35-44.

13. McCurdy SA, Williams ML, Ross MW, Kilonzo GP, Leshabari MT. A theme issue by, for, and about Africa: new injecting practice increases HIV risk among drug users in Tanzania. BMJ. 2005;331(7519):778.

14. McCurdy SA, Williams ML, Kilonzo GP, Ross MW, Leshabari MT. Heroin and HIV risk in Dar es Salaam, Tanzania: youth hangouts, mageto and injecting practices. AIDS Care. 2005;17 Suppl 1:S65-76.

15. Kalichman SC, Simbayi LC, Kagee A, Toefy Y, Jooste S, Cain D, et al. Associations of poverty, substance use, and HIV transmission risk behaviors in three South African communities. Soc Sci Med. 2006;62(7):1641-9.

16. Scheibe A, Makapela D, Brown B, dos Santos M, Hariga F, Virk H, et al. HIV prevalence and risk among people who inject drugs in five South African cities. Int J Drug Policy. 2016;30:107-15.

17. van Heerden MS, Grimsrud AT, Seedat S, Myer L, Williams DR, Stein DJ. Patterns of substance use in South Africa: results from the South African Stress and Health study. S Afr Med J. 2009;99(5 Pt 2):358-66.

18. Nampula. Africa is heroin's new highway to the west. The Economist. 2019; January 31, 2019.

19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.

20. Handanagic S, Finlayson T, Burnett JC, Broz D, Wejnert C, National HIVBSSG. HIV Infection and HIV-Associated Behaviors Among Persons Who Inject Drugs - 23 Metropolitan Statistical Areas, United States, 2018. MMWR Morb Mortal Wkly Rep. 2021;70(42):1459-65.

21. WHO Assist Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183-94.

22. Rowan GA, Joe GW, Lehman WE, Knight K. A Brief Assessment for HIV Risk: The TCU HVHP Form. J Correct Health Care. 2016;22(3):225-39.

23. Lafort Y, Greener R, Roy A, Greener L, Ombidi W, Lessitala F, et al. Where Do Female Sex Workers Seek HIV and Reproductive Health Care and What Motivates These Choices? A Survey in 4 Cities in India, Kenya, Mozambique and South Africa. PLoS One. 2016;11(8):e0160730.

24. Myers BJ, Louw J, Pasche SC. Inequitable access to substance abuse treatment services in Cape Town, South Africa. Subst Abuse Treat Prev Policy. 2010;5:28.

25. Scheibe A SS, Versfeld A, Howell S, Marks M. Safe treatment and treatment of safety: call for a harm-reduction approach to drug-use disorders in South Africa. South African Health Review. 2017;2017(1):197 - 204.

26. Marks M, Scheibe A, Shelly S. High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion. Harm Reduct J. 2020;17(1):25.

27. Marks M WM, Shelly S. Police as advocates for harm reduction during COVID-19 in Durban: Shifting the dominant narrative. Acta Criminologica: African Journal of Criminology & Victimology Special Edition: Impact of COVID-19. 2020;33(3).

28. Treves-Kagan S, Steward WT, Ntswane L, Haller R, Gilvydis JM, Gulati H, et al. Why increasing availability of ART is not enough: a rapid, community-based study on how HIV-related stigma impacts engagement to care in rural South Africa. BMC Public Health. 2016;16:87.

29. HIV/TB Care. Statement in response to media reports of inappropriately discarded needles and syringes in Durban 2018 [Available from: <u>https://tbhivcare.org/statement-response-media-reports-inappropriately-discarded-needles-syringes-durban/</u>.

30. Peltzer K, Phaswana-Mafuya N. Drug use among youth and adults in a population-based survey in South Africa. S Afr J Psychiatr. 2018;24:1139.

31. Scheibe A, Shelly S, Gerardy T, von Homeyer Z, Schneider A, Padayachee K, et al. Sixmonth retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa. Addict Sci Clin Pract. 2020;15(1):13.